Valsartan

• 

  Subject Areas on Research

  • Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. 
  • Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. 
  • Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. 
  • Blockade of angiotensin II type 2 receptor by PD123319 inhibits osteogenic differentiation of human mesenchymal stem cells via inhibition of extracellular signal-regulated kinase signaling. 
  • Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions. 
  • Cardiac protection: evolving role of angiotensin receptor blockers. 
  • Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. 
  • Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. 
  • Determining the most appropriate components for a composite clinical trial outcome. 
  • Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. 
  • Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. 
  • Effect of nateglinide on the incidence of diabetes and cardiovascular events. 
  • Effect of valsartan on the incidence of diabetes and cardiovascular events. 
  • Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. 
  • Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. 
  • Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). 
  • Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. 
  • Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. 
  • Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. 
  • Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). 
  • Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. 
  • Left ventricular assessment in myocardial infarction: the VALIANT registry. 
  • Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. 
  • Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. 
  • Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. 
  • Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. 
  • Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). 
  • Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. 
  • Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. 
  • Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. 
  • Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. 
  • Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. 
  • Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. 
  • Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. 
  • Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. 
  • Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. 
  • Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. 
  • Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. 
  • Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure). 
  • Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Therapeutic implications of high-dose angiotensin receptor blocker monotherapy in mild-to-moderate hypertensive patients. 
  • Use of valsartan in post-myocardial infarction and heart failure patients. 
  • Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). 
  • VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. 
  • Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. 
  • Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. 
  • Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. 
  • Valsartan, captopril, or both in myocardial infarction. 
  • Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.